The companies didn’t disclose the financial particulars of the pharma partners deal, but they plan to use MDxHealth’s PredictMDx test to determine which brain cancer patients might benefit from Merck KGaA’s in-the-pipeline cilengitide.
Under the pharma partners agreement, Merck KGaA will help MDxHealth get its test developed and approved, and then, assuming cilengitide gets a regulatory OK, the two will co-launch the drug and companion diagnostic.
For further deal information visit Current Agreements (subscription required)
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity